A SECRET WEAPON FOR "3

All enrolled patients who gained at the least a person dose of zosuquidar or placebo all through induction were monitored to the incidence of adverse events (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse events had been connected to the duration of prolonged and major myelosuppression as is predicted with inductio